Jun 1st, 2012
The Centers for Medicare & Medicaid Services (CMS) recently revised the National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4) to add coverage for the treatment of bronchiolitis obliterans syndrome (BOS) following lung allograft transplantation. Medicare coverage is effective for services rendered on or after April 30, 2012 when provided under a clinical research study a...
Oct 1st, 2011
Keep safe by using coverage analysis as a good risk management strategy. By Duwayne Barrett, MBA, RPSGT, CPC-P Clinical trials are an end stage in the lengthy research process of finding better ways to prevent, diagnose and treat disease. Like all health care services, however, clinical trials (ICD-9-CM code V70.7 Examination of participant in clinical ...
In Coding
Jan 28th, 2011
The Centers for Medicare & Medicaid Services (CMS) updated, Jan. 14, a national coverage determination (NCD) to add home use of oxygen to treat cluster headaches as a Part B durable medical equipment (DME) benefit when performed under a clinical trial. Code Home Oxygen Use for Cluster Headaches was last modified: July 5th, 2011 by admin aapc...
In Billing
Oct 15th, 2010
Effective for claims with service dates on or after Aug. 4, Medicare will nationally cover the use of allogenic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) when provided in a Medicare-approved clinical study under Coverage Evidence Development (CED). In all other settings, HSCT for MDS is nationally non-covered by Medicare. MDS refers to ...
In CMS
Jan 18th, 2010
August of last year, the Centers for Medicare & Medicaid Services (CMS) rendered a final National Coverage Determination (NCD) for warfarin responsiveness via pharmacogenomic testing. The news was not good. In short, CMS said there was insufficient evidence to support such testing improves health outcomes. The agency also said, however, that there was evidence to support pharmacogenomic testing...